RUNX1单位点与多位点突变急性髓系白血病的临床特征及预后比较
该回顾性队列研究纳入145例RUNX1突变AML患者,比较单位点(123例)与多位点(22例)突变的临床特征及预后。两组在年龄、血细胞计数、核型、融合基因、预后分层、首疗程诱导缓解率、中位OS及RFS上均无显著差异;多位点组共突变基因数更多。异基因造血干细胞移植是两组OS和RFS的独立保护因素。
要点
- RUNX1单位点与多位点突变AML在临床特征、治疗反应及远期预后上无显著差异。
- 多位点突变组共突变基因中位数高于单位点组(5个对3个,P=0.001)。
- 异基因造血干细胞移植是两组患者OS和RFS的独立保护因素。
核心结论
- 伴RUNX1单位点突变和多位点突变的AML患者在临床特征、治疗反应及远期预后上无明显差异。
- allo-HSCT能有效改善两组患者的生存结局。
研究设计与样本
- 本研究为回顾性队列研究。
- 选取2017年6月至2023年6月于苏州大学附属第一医院诊治的145例伴RUNX1突变AML患者。
- 单位点突变患者123例,多位点突变患者22例。
- 主要观察指标包括OS时间、RFS时间及首疗程诱导缓解率(完全缓解率和血细胞未完全恢复的完全缓解率之和)。
主要发现
- 全部145例患者中,男87例,女58例,中位年龄49(17~78)岁。
- 单位点突变患者和多位点突变患者的年龄、性别、初诊时血细胞计数、染色体核型、融合基因、预后分层等特征差异均无统计学意义(均P>0.05)。
- 单位点突变患者共突变基因中位数为3(0~11)个,多位点突变患者为5(2~10)个,后者多于前者(P=0.001),但两组间共突变基因谱分布差异无统计学意义(P>0.05)。
- 两组首疗程诱导缓解率(53.3%对50.0%,P=0.819)、中位OS时间(45.67个月对36.53个月,P=0.942)及中位RFS时间(17.13个月对21.17个月,P=0.679)差异均无统计学意义。
- 单位点突变组接受allo-HSCT患者的3年OS率及RFS率分别为74.7%和58.5%,显著高于未移植患者的31.2%和27.9%(均P<0.001);多位点突变组接受allo-HSCT患者的3年OS率及RFS率分别为69.2%和69.2%,亦显著高于未移植患者的33.3%和0(P=0.003及P=0.001)。
临床怎么用
- 对于伴RUNX1单位点或多位点突变的AML患者,allo-HSCT与改善生存结局相关,应考虑作为治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To compare the clinical characteristics and prognosis of patients with acute myeloid leukemia (AML) harboring single-site versus multi-site mutations in the RUNX1 gene. Methods: This study was a retrospective cohort study. 145 patients with RUNX1-mutated AML treated at the First Affiliated Hospital of Soochow University between June 2017 and June 2023 were selected. Single-site RUNX1 mutations were observed in 123 patients, whereas multi-site mutations were detected in 22 patients. The outcomes of interest included overall survival (OS), recurrence-free survival (RFS), and the first-course induction remission rate, defined as the sum of complete remission and complete remission with incomplete hematologic recovery. Results: A total of 145 patients with RUNX1-mutated AML were included, including 87 males and 58 females, with a median age of 49 years (range, 17-78 years). The two groups showed no significant differences in age, sex composition, peripheral blood counts at diagnosis, karyotype, fusion genes, or risk stratification (all P>0.05). The median number of co-occurring gene mutations was 3 (range, 0-11) in the single-site group and 5 (range, 2-10) in the multi-site group, indicating a significantly higher number in the latter (P=0.001). However, the distribution of co-occurring mutations did not differ significantly between groups (P>0.05). There were no significant between-group differences in the first-course induction remission rate (53.3% vs 50.0%, P=0.819), median OS (45.67 vs 36.53 months, P=0.942), or median RFS (17.13 vs 21.17 months, P=0.679). In the single-site mutation group, patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) achieved 3-year OS and RFS rates of 74.7% and 58.5%, respectively, significantly higher than the 31.2% and 27.9% among those without transplantation (both P<0.001). In the multi-site mutation group, the 3-year OS and RFS rates were 69.2% and 69.2%, respectively, among allo-HSCT recipients, significantly higher than 33.3% and 0, respectively, among nonrecipients (P=0.003 and P=0.001, respectively). Multivariate Cox proportional hazards analysis identified allo-HSCT as an independent protective factor for OS (single-site group: HR=0.256, P<0.001; multi-site group: HR=0.164, P=0.043) and RFS (single-site group: HR=0.528, P=0.025; multi-site group: HR=0.142, P=0.030) . Conclusion: Patients with AML harboring single-site and multi-site RUNX1 mutations did not differ significantly in clinical characteristics, treatment response, or long-term prognosis. Allo-HSCT was associated with improved survival outcomes in both groups. 目的: 比较伴RUNX1单位点与多位点突变急性髓系白血病(AML)患者的临床特征及预后。 方法: 本研究为回顾性队列研究。选取2017年6月至2023年6月于苏州大学附属第一医院诊治的145例伴RUNX1突变AML患者。其中单位点突变患者123例,多位点突变患者22例,主要观察指标包括总生存(OS)时间、无复发生存(RFS)时间及首疗程诱导缓解率(完全缓解率和血细胞未完全恢复的完全缓解率之和)。 结果: 全部145例RUNX1突变阳性的AML患者中,男87例,女58例,中位年龄49(17~78)岁,单位点突变患者和多位点突变患者的年龄、性别、初诊时的血细胞计数、染色体核型、融合基因、预后分层等特征差异均无统计学意义(均P>0.05)。单位点突变患者共突变基因中位数为3(0~11)个,多位点突变患者共突变基因中位数为5(2~10)个,后者多于前者(P=0.001),但两组间共突变基因谱分布差异无统计学意义(P>0.05)。两组首疗程诱导缓解率(53.3%对50.0%,P=0.819)、中位OS时间(45.67个月对36.53个月,P=0.942)及中位RFS时间(17.13个月对21.17个月,P=0.679)差异均无统计学意义。单位点突变组接受异基因造血干细胞移植(allo-HSCT)患者的3年OS率及RFS率分别为74.7%和58.5%,显著高于未移植患者的31.2%和27.9%(均P<0.001);多位点突变组接受allo-HSCT患者的3年OS率及RFS率分别为69.2%和69.2%,亦显著高于未移植患者的33.3%和0(P=0.003及P=0.001)。多因素Cox回归分析显示,allo-HSCT是两组患者OS(单位点突变组:HR=0.256,P<0.001;多位点突变组:HR=0.164,P=0.043)及RFS(单位点突变组:HR=0.528,P=0.025;多位点突变组:HR=0.142,P=0.030)的独立保护因素。 结论: 伴RUNX1单位点突变和多位点突变的AML患者在临床特征、治疗反应及远期预后上无明显差异,allo-HSCT能有效改善两组患者的生存结局。.
引用
- Li C, Wu YX, Ma X, et al. [Clinical characteristics and prognosis of acute myeloid leukemia patients with RUNX1 single-site and multiple-site gene mutations]. Zhonghua Xue Ye Xue Za Zhi. 2026. PMID: 42706154. doi:10.3760/cma.j.cn121090-20251020-00473
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。